BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12962565)

  • 1. [Detection of minimal residual disease in Ph+/bcr-abl+ acute lymphoblast leukemia by cytogenetic analysis, nested-PCR and flow cytometry].
    Xue F; Dong ZR; Zhang B; Gao LX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Aug; 11(4):372-5. PubMed ID: 12962565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
    Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
    Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
    Gleissner B; Rieder H; Thiel E; Fonatsch C; Janssen LA; Heinze B; Janssen JW; Schoch C; Goekbuget N; Maurer J; Hoelzer D; Bartram CR
    Leukemia; 2001 Dec; 15(12):1834-40. PubMed ID: 11753602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.
    Yokota H; Tsuno NH; Tanaka Y; Fukui T; Kitamura K; Hirai H; Osumi K; Itou N; Satoh H; Okabe M; Nakahara K
    Leukemia; 2002 Jun; 16(6):1167-75. PubMed ID: 12040449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of phosphotyrosine in chronic myeloid leukemia cells with PY20 antibody and its clinical applications].
    Tian J; Cheng H; Xu KL; Pan XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1056-60. PubMed ID: 19698259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.
    Radich JP
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):91-103. PubMed ID: 11987918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
    Thörn I; Botling J; Hermansson M; Lönnerholm G; Sundström C; Rosenquist R; Barbany G
    Leuk Res; 2009 Aug; 33(8):1047-54. PubMed ID: 19157547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction].
    Huang W; Cao Q; Lu Y
    Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):662-5, 708. PubMed ID: 7866899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
    Suh SP; Kee SJ; Lim WH; Song JW; Lee SK; Kim JP; Shin JH; Ryang DW
    Clin Chem Lab Med; 2000 Sep; 38(9):939-44. PubMed ID: 11097354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients.
    Janssen JW; Fonatsch C; Ludwig WD; Rieder H; Maurer J; Bartram CR
    Leukemia; 1992 May; 6(5):463-4. PubMed ID: 1593911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
    Chen ZX; Kaeda J; Saunders S; Goldman JM
    Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relationship between the persistence of the BCR/ABL gene and relapse in adult patients with acute lymphoblastic leukemia].
    Anguita E; Villegas A; González FA; del Potro E; Martínez R; Alvarez A; Díaz-Mediavilla J; Ferro MT; Espinós D
    Med Clin (Barc); 1999 Apr; 112(13):481-4. PubMed ID: 10353112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
    van Rhee F; Marks DI; Lin F; Szydlo RM; Hochhaus A; Treleaven J; Delord C; Cross NC; Goldman JM
    Leukemia; 1995 Feb; 9(2):329-35. PubMed ID: 7869772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
    Pane F; Cimino G; Izzo B; Camera A; Vitale A; Quintarelli C; Picardi M; Specchia G; Mancini M; Cuneo A; Mecucci C; Martinelli G; Saglio G; Rotoli B; Mandelli F; Salvatore F; Foà R;
    Leukemia; 2005 Apr; 19(4):628-35. PubMed ID: 15744351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
    Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH).
    Mancini M; Nanni M; Sirleto P; De Cuia MR; Castoldi GL; Cilloni D; Cimino G; Mecucci C; Pane F; Annino L; Di Raimondo F; Santoro A; Specchia G; Tedeschi A; Todeschini G; Foá R;
    Hematol J; 2001; 2(1):54-60. PubMed ID: 11920234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.